SG10201912199XA - Anti-tim-3 antibodies and use thereof - Google Patents
Anti-tim-3 antibodies and use thereofInfo
- Publication number
- SG10201912199XA SG10201912199XA SG10201912199XA SG10201912199XA SG10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA SG 10201912199X A SG10201912199X A SG 10201912199XA
- Authority
- SG
- Singapore
- Prior art keywords
- tim
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016096924 | 2016-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201912199XA true SG10201912199XA (en) | 2020-02-27 |
Family
ID=61246369
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901548SA SG11201901548SA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
| SG10201912199XA SG10201912199XA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901548SA SG11201901548SA (en) | 2016-08-26 | 2017-08-25 | Anti-tim-3 antibodies and use thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11203637B2 (en) |
| EP (2) | EP3504243A4 (en) |
| JP (2) | JP6968872B2 (en) |
| KR (1) | KR102460525B1 (en) |
| CN (3) | CN109790218B (en) |
| AU (1) | AU2017317227A1 (en) |
| BR (1) | BR112019003976A2 (en) |
| CA (1) | CA3034962A1 (en) |
| EA (1) | EA201990594A1 (en) |
| MX (1) | MX2019002242A (en) |
| NZ (1) | NZ751246A (en) |
| SG (2) | SG11201901548SA (en) |
| TW (2) | TW202246347A (en) |
| WO (1) | WO2018036561A1 (en) |
| ZA (1) | ZA201901113B (en) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013400609B9 (en) * | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
| WO2016000619A1 (en) | 2014-07-03 | 2016-01-07 | Beigene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
| CN109475536B (en) | 2016-07-05 | 2022-05-27 | 百济神州有限公司 | Combination of a PD-l antagonist and a RAF inhibitor for the treatment of cancer |
| AU2017297506A1 (en) | 2016-07-14 | 2019-02-21 | Bristol-Myers Squibb Company | Antibodies against TIM3 and uses thereof |
| EP4353747A2 (en) | 2016-08-19 | 2024-04-17 | BeiGene Switzerland GmbH | Combination of zanubrutinib with an anti-cd20 or an anti-pd-1 antibody for use in treating cancer |
| CN109790218B (en) | 2016-08-26 | 2023-03-03 | 百济神州有限公司 | anti-TIM-3 antibodies and uses thereof |
| BR112019008861A2 (en) | 2016-11-01 | 2019-07-09 | Anaptysbio Inc | antibodies directed against t-cell immunoglobulin and mucin 3 (tim-3) protein |
| CA3049536A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| US11597768B2 (en) | 2017-06-26 | 2023-03-07 | Beigene, Ltd. | Immunotherapy for hepatocellular carcinoma |
| WO2019032628A1 (en) | 2017-08-07 | 2019-02-14 | The Regents Of The University Of California | Platform for generating safe cell therapeutics |
| CN111801334B (en) | 2017-11-29 | 2023-06-09 | 百济神州瑞士有限责任公司 | Treatment of indolent or invasive B-cell lymphomas using combinations comprising BTK inhibitors |
| EP3768725A4 (en) * | 2018-03-20 | 2021-06-02 | Wuxi Biologics Ireland Limited | Novel anti-tim-3 antibodies |
| PE20210665A1 (en) | 2018-03-23 | 2021-03-31 | Bristol Myers Squibb Co | ANTIBODIES AGAINST MICA AND / OR MICB AND ITS USES |
| CN111989341B (en) | 2018-04-12 | 2023-06-02 | 南京维立志博生物科技有限公司 | Antibodies that bind TIM-3 and uses thereof |
| MX2021001516A (en) * | 2018-08-20 | 2021-04-19 | Jiangsu Hengrui Medicine Co | Use of tim-3 antibody in preparation of medicines for treating tumors. |
| JP2021534735A (en) * | 2018-08-21 | 2021-12-16 | アルバート アインシュタイン カレッジ オブ メディスンAlbert Einstein College Of Medicine | Monoclonal antibody against human Tim-3 |
| EP3976831A1 (en) | 2019-05-30 | 2022-04-06 | Bristol-Myers Squibb Company | Multi-tumor gene signatures for suitability to immuno-oncology therapy |
| CN114127315A (en) | 2019-05-30 | 2022-03-01 | 百时美施贵宝公司 | Method of identifying subjects suitable for immunooncology (I-O) therapy |
| US20220233691A1 (en) | 2019-05-30 | 2022-07-28 | Bristol-Myers Squibb Company | Cell localization signature and combination therapy |
| AU2020296124A1 (en) * | 2019-06-21 | 2022-01-27 | Single Cell Technology, Inc. | Anti-TIM-3 antibodies |
| CN110498855A (en) * | 2019-07-25 | 2019-11-26 | 钟小泉 | A kind of TIM-3 antibody and application thereof |
| MX2022006149A (en) * | 2019-11-21 | 2022-06-17 | Beigene Ltd | Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies. |
| CN111995681B (en) * | 2020-05-09 | 2022-03-08 | 华博生物医药技术（上海）有限公司 | anti-TIGIT antibody, preparation method and application thereof |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| IL303648A (en) | 2020-12-28 | 2023-08-01 | Bristol Myers Squibb Co | Antibody compositions and methods of use thereof |
| CN113087800A (en) * | 2021-03-12 | 2021-07-09 | 北京广未生物科技有限公司 | Application of bone marrow mesenchymal stem cells in combination with monoclonal antibody in treatment of cancer |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| CN117377692A (en) * | 2021-04-23 | 2024-01-09 | 苏州逻晟生物医药有限公司 | TIM-3-targeting antibodies and uses thereof |
| WO2023178329A1 (en) | 2022-03-18 | 2023-09-21 | Bristol-Myers Squibb Company | Methods of isolating polypeptides |
| WO2023235847A1 (en) | 2022-06-02 | 2023-12-07 | Bristol-Myers Squibb Company | Antibody compositions and methods of use thereof |
| WO2024041651A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies |
| WO2024044675A1 (en) | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies |
| WO2024041652A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US7563874B2 (en) | 1998-08-31 | 2009-07-21 | The Regents Of The University Of California | Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins |
| NZ530451A (en) * | 2001-06-29 | 2008-04-30 | Univ Leland Stanford Junior | TIM gene sequences and their use in immunological disorders and cancer |
| AU2003303082B2 (en) | 2002-01-30 | 2009-07-02 | Dana-Farber Cancer Institute, Inc. | Compositions and methods related to TIM-3, a Th1-specific cell surface molecule |
| JP2011500730A (en) * | 2007-10-26 | 2011-01-06 | ガバニング カウンセル オブ ザ ユニバーシティ オブ トロント | Treatment and diagnostic method using Tim-3 |
| EP2303926A1 (en) | 2008-06-20 | 2011-04-06 | Oklahoma Medical Research Foundation | Immunogenic memapsin 2 -secretase peptides and methods of use |
| KR101846590B1 (en) | 2010-06-11 | 2018-04-09 | 교와 핫꼬 기린 가부시키가이샤 | Anti-tim-3 antibody |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| CN102492038B (en) * | 2011-12-09 | 2014-05-28 | 中国人民解放军军事医学科学院基础医学研究所 | Anti-human Tim-3 neutralized monoclonal antibody L3D and application thereof |
| EP3338793A1 (en) * | 2013-08-28 | 2018-06-27 | AbbVie Stemcentrx LLC | Novel sez6 modulators and methods of use |
| AU2013400609B9 (en) | 2013-09-13 | 2020-03-05 | Beigene Switzerland Gmbh | Anti-PD1 antibodies and their use as therapeutics and diagnostics |
| CN103721255A (en) * | 2014-01-07 | 2014-04-16 | 苏州大学 | Application of co-blocking of PD-1 and TIM-3 signal paths to anti-stomach-cancer treatment |
| JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
| WO2016000619A1 (en) * | 2014-07-03 | 2016-01-07 | Beigene, Ltd. | Anti-pd-l1 antibodies and their use as therapeutics and diagnostics |
| EP3212231B1 (en) * | 2014-10-27 | 2021-04-28 | Agency For Science, Technology And Research | Anti-tim-3 antibodies |
| LT3215532T (en) * | 2014-11-06 | 2020-01-10 | F. Hoffmann-La Roche Ag | Anti-tim3 antibodies and methods of use |
| CN109790218B (en) | 2016-08-26 | 2023-03-03 | 百济神州有限公司 | anti-TIM-3 antibodies and uses thereof |
-
2017
- 2017-08-25 CN CN201780052246.5A patent/CN109790218B/en active Active
- 2017-08-25 US US16/328,047 patent/US11203637B2/en active Active
- 2017-08-25 SG SG11201901548SA patent/SG11201901548SA/en unknown
- 2017-08-25 SG SG10201912199XA patent/SG10201912199XA/en unknown
- 2017-08-25 EP EP17842983.3A patent/EP3504243A4/en active Pending
- 2017-08-25 AU AU2017317227A patent/AU2017317227A1/en active Pending
- 2017-08-25 TW TW111125696A patent/TW202246347A/en unknown
- 2017-08-25 WO PCT/CN2017/099098 patent/WO2018036561A1/en unknown
- 2017-08-25 TW TW106129066A patent/TWI769174B/en active
- 2017-08-25 JP JP2019511565A patent/JP6968872B2/en active Active
- 2017-08-25 CN CN202310121523.0A patent/CN116655790A/en active Pending
- 2017-08-25 CA CA3034962A patent/CA3034962A1/en active Pending
- 2017-08-25 EP EP21190971.8A patent/EP3970749A1/en active Pending
- 2017-08-25 EA EA201990594A patent/EA201990594A1/en unknown
- 2017-08-25 MX MX2019002242A patent/MX2019002242A/en unknown
- 2017-08-25 NZ NZ751246A patent/NZ751246A/en unknown
- 2017-08-25 CN CN202310121525.XA patent/CN116478290A/en active Pending
- 2017-08-25 BR BR112019003976A patent/BR112019003976A2/en unknown
- 2017-08-25 KR KR1020197007868A patent/KR102460525B1/en active IP Right Grant
-
2019
- 2019-02-21 ZA ZA2019/01113A patent/ZA201901113B/en unknown
-
2021
- 2021-10-27 JP JP2021175867A patent/JP7158552B2/en active Active
- 2021-11-15 US US17/526,817 patent/US20220135675A1/en not_active Abandoned
-
2023
- 2023-09-27 US US18/475,552 patent/US20240076375A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019529373A (en) | 2019-10-17 |
| US11203637B2 (en) | 2021-12-21 |
| AU2017317227A1 (en) | 2019-04-11 |
| EP3970749A1 (en) | 2022-03-23 |
| CN116655790A (en) | 2023-08-29 |
| WO2018036561A1 (en) | 2018-03-01 |
| CA3034962A1 (en) | 2018-03-01 |
| KR102460525B1 (en) | 2022-11-01 |
| US20220135675A1 (en) | 2022-05-05 |
| EP3504243A1 (en) | 2019-07-03 |
| US20190276533A1 (en) | 2019-09-12 |
| EA201990594A1 (en) | 2019-08-30 |
| CN116478290A (en) | 2023-07-25 |
| ZA201901113B (en) | 2020-10-28 |
| TW201819414A (en) | 2018-06-01 |
| CN109790218A (en) | 2019-05-21 |
| US20240076375A1 (en) | 2024-03-07 |
| TWI769174B (en) | 2022-07-01 |
| CN109790218B (en) | 2023-03-03 |
| SG11201901548SA (en) | 2019-03-28 |
| KR20190042037A (en) | 2019-04-23 |
| EP3504243A4 (en) | 2020-03-11 |
| BR112019003976A2 (en) | 2019-05-28 |
| JP7158552B2 (en) | 2022-10-21 |
| JP2022027659A (en) | 2022-02-10 |
| MX2019002242A (en) | 2019-08-16 |
| NZ751246A (en) | 2023-04-28 |
| TW202246347A (en) | 2022-12-01 |
| JP6968872B2 (en) | 2021-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290842A (en) | Anti-cd73 antibodies and uses thereof | |
| IL268206A (en) | Bcma-targeting antibody and use thereof | |
| SG10201912199XA (en) | Anti-tim-3 antibodies and use thereof | |
| ZA202102905B (en) | Anti-galectin-9 antibodies and uses thereof | |
| IL266738A (en) | Novel antibodies and uses thereof | |
| ZA202101318B (en) | Anti-phf-tau antibodies and uses thereof | |
| IL262095A (en) | Anti-pacap antibodies and uses thereof | |
| IL268734A (en) | Anti-lag-3 antibodies and uses thereof | |
| IL271477A (en) | Anti-cd166 antibodies and uses thereof | |
| EP3541840C0 (en) | Anti-hla-g antibodies and use thereof | |
| ZA201901935B (en) | Anti-il-33 antibodies and uses thereof | |
| IL269134A (en) | Anti-par2 antibodies and uses thereof | |
| IL247315A0 (en) | Anti-acth antibodies and use thereof | |
| IL263242A (en) | Cytosol-penetrating antibody and use thereof | |
| IL272476A (en) | Anti-apelin antibodies and uses thereof | |
| IL266049A (en) | Anti-o1 antibodies and uses thereof | |
| IL273157A (en) | Axl-specific antibodies and uses thereof | |
| IL266082A (en) | Anti-chikv antibodies and uses thereof | |
| IL264417A (en) | Anti-o2 antibodies and uses thereof | |
| IL271398A (en) | Anti-l1-cam antibodies and uses thereof | |
| GB201712032D0 (en) | Antibodies and uses thereof | |
| SG11202003585VA (en) | Anti-vista antibody and use thereof | |
| ZA201906248B (en) | Anti-ceacam1 antibody and use thereof |